Abivax S.A.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AAVXF research report →
Companywww.abivax.com
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer.
- CEO
- Marc de Garidel
- IPO
- 2016
- Employees
- 69
- HQ
- Paris, FR
Price Chart
Valuation
- Market Cap
- $9.17B
- P/E
- -21.29
- P/S
- 0.00
- P/B
- 15.72
- EV/EBITDA
- -30.75
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -165.19%
- ROIC
- -47.96%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-335,976,116 · -90.63%
- EPS
- $-4.83 · -72.50%
- Op Income
- $-250,531,130
- FCF YoY
- -4.82%
Performance & Tape
- 52W High
- $133.40
- 52W Low
- $5.81
- 50D MA
- $119.15
- 200D MA
- $69.99
- Beta
- -0.19
- Avg Volume
- 198
Get TickerSpark's AI analysis on AAVXF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our AAVXF Coverage
We haven't published any research on AAVXF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AAVXF Report →